BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 8293765)

  • 1. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation.
    Lugnier C; Komas N
    Eur Heart J; 1993 Nov; 14 Suppl I():141-8. PubMed ID: 8293765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors.
    Komas N; Lugnier C; Stoclet JC
    Br J Pharmacol; 1991 Oct; 104(2):495-503. PubMed ID: 1665741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
    Eckly AE; Lugnier C
    Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The L-arginine-NO pathway and cyclic GMP in the vessel wall.
    Stoclet JC
    Z Kardiol; 1991; 80 Suppl 7():87-90. PubMed ID: 1665267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
    Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
    Santos-Silva AJ; Cairrão E; Morgado M; Alvarez E; Verde I
    Eur J Pharmacol; 2008 Mar; 582(1-3):102-9. PubMed ID: 18234184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea.
    Ellis JL; Conanan ND
    J Pharmacol Exp Ther; 1995 Mar; 272(3):997-1004. PubMed ID: 7891355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
    Maurice DH
    Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic adenosine monophosphate and cyclic guanosine monophosphate-phosphodiesterase isoenzymes in human vagina: relation to nitric oxide synthase isoforms and vasoactive intestinal polypeptide-containing nerves.
    Uckert S; Oelke M; Waldkirch E; Stief CG; Albrecht K; Tröger HD; Jonas U; Andersson KE; Hedlund P
    Urology; 2005 Mar; 65(3):604-10. PubMed ID: 15780401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial cyclic GMP and cyclic AMP do not regulate the release of endothelium-derived relaxing factor/nitric oxide from bovine aortic endothelial cells.
    Kuhn M; Otten A; Frölich JC; Förstermann U
    J Pharmacol Exp Ther; 1991 Feb; 256(2):677-82. PubMed ID: 1847208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle.
    Torphy TJ; Undem BJ; Cieslinski LB; Luttmann MA; Reeves ML; Hay DW
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1213-23. PubMed ID: 8389856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta.
    Yu SM; Kuo SC
    Br J Pharmacol; 1995 Apr; 114(8):1587-94. PubMed ID: 7599926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of cyclic nucleotide-dependent protein kinases in cyclic AMP-mediated vasorelaxation.
    Eckly-Michel A; Martin V; Lugnier C
    Br J Pharmacol; 1997 Sep; 122(1):158-64. PubMed ID: 9298542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel.
    Lugnier C; Keravis T; Eckly-Michel A
    J Physiol Pharmacol; 1999 Dec; 50(4):639-52. PubMed ID: 10639014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
    Nicholson CD; Shahid M; Bruin J; Barron E; Spiers I; de Boer J; van Amsterdam RG; Zaagsma J; Kelly JJ; Dent G
    J Pharmacol Exp Ther; 1995 Aug; 274(2):678-87. PubMed ID: 7636728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
    Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
    Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
    Rose RJ; Liu H; Palmer D; Maurice DH
    Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the low Km cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone.
    Silver PJ; Lepore RE; O'Connor B; Lemp BM; Hamel LT; Bentley RG; Harris AL
    J Pharmacol Exp Ther; 1988 Oct; 247(1):34-42. PubMed ID: 2845058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of cyclic nucleotides in renal artery smooth muscle relaxation.
    Karsten AJ; Derouet H; Ziegler M; Eckert RE
    Urol Res; 2003 Feb; 30(6):367-73. PubMed ID: 12599016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects.
    Werkström V; Svensson A; Andersson KE; Hedlund P
    BJU Int; 2006 Aug; 98(2):414-23. PubMed ID: 16626307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.